ATXI logo

Avenue Therapeutics (ATXI) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 June 2017

Indexes:

Not included

Description:

Avenue Therapeutics (ATXI) is a biopharmaceutical company focused on developing and commercializing innovative therapies for pain management. Their lead product is an intravenous formulation of tramadol, aimed at providing effective pain relief in hospital settings. The company seeks to improve patient care through advanced treatment options.

Events Calendar

Earnings

Next earnings date:

Mar 18, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 26, 2024

Analyst ratings

Recent major analysts updates

11 Dec '23 Maxim Group
Buy
03 Apr '23 Aegis Capital
Buy
12 May '20 HC Wainwright & Co.
Buy
13 July '18 Oppenheimer
Outperform
25 June '18 H.C. Wainwright
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
ATXI
globenewswire.com09 October 2024

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.

Avenue Therapeutics to Participate in Upcoming Investor Conferences
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Avenue Therapeutics to Participate in Upcoming Investor Conferences
ATXI
globenewswire.com03 September 2024

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
globenewswire.com09 August 2024

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –

Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
ATXI
InvestorPlace29 November 2023

Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC), Davidow now holds a 14.5% stake in the specialty pharmaceutical company.

FAQ

  • What is the primary business of Avenue Therapeutics?
  • What is the ticker symbol for Avenue Therapeutics?
  • Does Avenue Therapeutics pay dividends?
  • What sector is Avenue Therapeutics in?
  • What industry is Avenue Therapeutics in?
  • What country is Avenue Therapeutics based in?
  • When did Avenue Therapeutics go public?
  • Is Avenue Therapeutics in the S&P 500?
  • Is Avenue Therapeutics in the NASDAQ 100?
  • Is Avenue Therapeutics in the Dow Jones?
  • When was Avenue Therapeutics's last earnings report?
  • When does Avenue Therapeutics report earnings?
  • Should I buy Avenue Therapeutics stock now?

What is the primary business of Avenue Therapeutics?

Avenue Therapeutics (ATXI) is a biopharmaceutical company focused on developing and commercializing innovative therapies for pain management. Their lead product is an intravenous formulation of tramadol, aimed at providing effective pain relief in hospital settings. The company seeks to improve patient care through advanced treatment options.

What is the ticker symbol for Avenue Therapeutics?

The ticker symbol for Avenue Therapeutics is NASDAQ:ATXI

Does Avenue Therapeutics pay dividends?

No, Avenue Therapeutics does not pay dividends

What sector is Avenue Therapeutics in?

Avenue Therapeutics is in the Healthcare sector

What industry is Avenue Therapeutics in?

Avenue Therapeutics is in the Biotechnology industry

What country is Avenue Therapeutics based in?

Avenue Therapeutics is headquartered in United States

When did Avenue Therapeutics go public?

Avenue Therapeutics's initial public offering (IPO) was on 27 June 2017

Is Avenue Therapeutics in the S&P 500?

No, Avenue Therapeutics is not included in the S&P 500 index

Is Avenue Therapeutics in the NASDAQ 100?

No, Avenue Therapeutics is not included in the NASDAQ 100 index

Is Avenue Therapeutics in the Dow Jones?

No, Avenue Therapeutics is not included in the Dow Jones index

When was Avenue Therapeutics's last earnings report?

Avenue Therapeutics's most recent earnings report was on 14 November 2024

When does Avenue Therapeutics report earnings?

The next expected earnings date for Avenue Therapeutics is 18 March 2025

Should I buy Avenue Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions